Fuller & Thaler Asset Management Inc. Has $1.04 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB)

Fuller & Thaler Asset Management Inc. increased its position in shares of Biogen Inc. (NASDAQ:BIIB) by 43.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 6,788 shares of the biotechnology company’s stock after buying an additional 2,053 shares during the quarter. Fuller & Thaler Asset Management Inc.’s holdings in Biogen were worth $1,038,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Pacer Advisors Inc. lifted its holdings in shares of Biogen by 13,574.7% in the 4th quarter. Pacer Advisors Inc. now owns 2,667,531 shares of the biotechnology company’s stock worth $407,919,000 after purchasing an additional 2,648,024 shares in the last quarter. Norges Bank acquired a new position in shares of Biogen during the fourth quarter valued at about $355,569,000. Van ECK Associates Corp increased its position in shares of Biogen by 977.9% during the fourth quarter. Van ECK Associates Corp now owns 1,066,460 shares of the biotechnology company’s stock worth $163,083,000 after acquiring an additional 967,523 shares in the last quarter. Invesco Ltd. lifted its position in Biogen by 30.6% in the 4th quarter. Invesco Ltd. now owns 2,128,807 shares of the biotechnology company’s stock valued at $325,537,000 after acquiring an additional 499,074 shares in the last quarter. Finally, FMR LLC boosted its stake in Biogen by 98.7% during the 4th quarter. FMR LLC now owns 757,570 shares of the biotechnology company’s stock valued at $115,848,000 after purchasing an additional 376,356 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.

Biogen Stock Down 0.6 %

BIIB stock opened at $118.84 on Friday. The stock has a 50-day simple moving average of $132.47 and a two-hundred day simple moving average of $149.39. Biogen Inc. has a twelve month low of $110.04 and a twelve month high of $238.00. The firm has a market capitalization of $17.40 billion, a PE ratio of 10.62, a PEG ratio of 1.51 and a beta of 0.06. The company has a quick ratio of 0.90, a current ratio of 1.35 and a debt-to-equity ratio of 0.27.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 EPS for the quarter, beating the consensus estimate of $3.43 by $0.01. Biogen had a net margin of 16.87% and a return on equity of 14.98%. On average, equities analysts predict that Biogen Inc. will post 15.83 EPS for the current fiscal year.

Insider Transactions at Biogen

In other news, Director Stephen A. Sherwin sold 8,760 shares of the business’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the completion of the transaction, the director now owns 11,318 shares of the company’s stock, valued at approximately $1,697,926.36. The trade was a 43.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

BIIB has been the subject of several analyst reports. BMO Capital Markets lowered their price objective on Biogen from $156.00 to $139.00 and set a “market perform” rating for the company in a research note on Thursday, February 13th. Canaccord Genuity Group lowered their price target on Biogen from $298.00 to $265.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Needham & Company LLC reiterated a “hold” rating on shares of Biogen in a research note on Friday. William Blair reiterated an “outperform” rating on shares of Biogen in a report on Monday, January 13th. Finally, Royal Bank of Canada upped their price objective on shares of Biogen from $221.00 to $225.00 and gave the stock an “outperform” rating in a research report on Tuesday. Eighteen analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $211.37.

Biogen Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.